203521-17-9

Basic information

• Product Name: 1-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]PIPERAZINE
• Synonyms: 1-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]PIPERAZINE;1-((6-Chloronaphthalen-2-yl)sulfonyl)piperazine
• CAS NO: 203521-17-9
• Molecular Formula: C₁₄H₁₅ClN₂O₂S
• Molecular Weight: 310.8
• Mol File: 203521-17-9.mol
• Article Data: 3

Chemical Properties

• Melting Point: 248-251 °C(Solv: ethyl acetate (141-78-6))
• Boiling Point: 498.8°C at 760 mmHg
• Flash Point: 255.5°C
• Appearance: /
• Density: 1.369g/cm³
• Vapor Pressure: 4.37E-10mmHg at 25°C
• Refractive Index: 1.642
• Storage Temp.: 2-8°C
• PKA: 7.69±0.10(Predicted)
• CAS DataBase Reference: 1-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]PIPERAZINE(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]PIPERAZINE(203521-17-9)
• EPA Substance Registry System: 1-[(6-CHLORO-2-NAPHTHALENYL)SULFONYL]PIPERAZINE(203521-17-9)

Safety Data

• Hazardous Substances Data: 203521-17-9(Hazardous Substances Data)

Usage

Sulfonyl piperazine derivative

Contains a piperazine ring with a sulfonyl group attached to one of the nitrogen atoms
This describes the core structure of the compound, which is derived from the piperazine molecule by adding a sulfonyl group.

Chloro-substituted naphthalene ring

Contains a chlorine atom attached to the naphthalene ring
This highlights the presence of a chlorine atom in the naphthalene ring, which is part of the compound's structure.

Pharmacological properties

Activity as a serotonin receptor antagonist
This indicates that the compound has the potential to interact with serotonin receptors, which could be useful in treating conditions like schizophrenia.

Therapeutic potential

Possible use for conditions such as schizophrenia
This suggests that the compound may have therapeutic applications in treating mental health disorders, specifically schizophrenia.

Fluorescent probe

Under investigation for its potential use in detecting certain metal ions
This property indicates that the compound may be useful in chemical analysis, particularly in the detection of metal ions.

Fields of interest

Medicinal chemistry, pharmacology, and chemical biology
These are the scientific disciplines in which researchers are studying the compound for its potential applications and properties.

InChI:InChI=1/C14H15ClN2O2S/c15-13-3-1-12-10-14(4-2-11(12)9-13)20(18,19)17-7-5-16-6-8-17/h1-4,9-10,16H,5-8H2

Upstream product

• 216866-88-5 1-(tert-butoxycarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)piperazine 
• 91-58-7 2-chloronaphthalene 
• 102153-63-9 6-chloronaphth-2-ylsulfonyl chloride 
• 102878-14-8 6-chloro-2-naphthalenesulphonic acid 

Downstream Products

• 207798-71-8 1-[(6-chloronaphthalen-2-yl)sulfonyl]-4-[4-(pyridin-4-yl)benzoyl]piperazine 
• 216957-07-2 1-[4-(N-tert-butoxycarbonylaminomethyl)benzoyl]-4-[(6-chloronaphthalen-2-yl)sulfonyl]piperazine 
• 216957-26-5 1-(trans-4-tert-butoxycarbonylaminocyclohexane-1-ylcarbonyl)-4-(6-chloronaphthalene-2-sulfonyl)piperazine 

Relevant articles and documents

Orally active factor Xa inhibitors: 4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine derivatives

In our investigation of factor Xa inhibitors, a series of 1-(6-chloronaphthalen-2-yl)sulfonyl-4-(4,5,6,7-tetrahydrothiazolo[5,4-c] pyridine-2-carbonyl)piperazines 3a-i were synthesized. In vitro inhibitory activities of the compounds against factor Xa and coagulation are summarized. Among the compounds, 3c and 3d, possessing a carbamoyl or N-methylcarbamoyl moiety, showed potent inhibitory activities when administered orally to rats.

Sulfonamide derivatives, their production and use

The present invention provides compounds which specifically inhibit FXa, which are effective when orally administered and which are useful as a safe medicine for the prevention or treatment of diseases caused by thrombus or infarction. Compounds of this invention are piperazinones of the formula: wherein R1is an optionally substituted hydrocarbon group or an optionally substituted heterocyclic group; the ring A is an optionally substituted divalent nitrogen-containing heterocyclic group, in addition to being substituted by the group of the formula: and the group of the formula: Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent heterocyclic group; X is a direct bond or an optionally substituted alkylene chain; Z is (1) an amino group substituted with an optionally substituted hydrocarbon group, (2) an optionally substituted imino group or (3) an optionally substituted nitrogen-containing heterocyclic group; provided that when X is a direct bond and Z is an optionally substituted 6-membered nitrogen-containing aromatic heterocyclic group, Y is an optionally substituted divalent hydrocarbon group or an optionally substituted divalent unsaturated heterocyclic group; or a salt thereof.